We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology Newsfeed
  • Blog
  • Events
  • Popular
  • About
  • Login
  • Register
  • Your Basket
  • Blog
  • Events
  • Popular
  • About
  • Login
  • Register
  • Newsfeed
  • Navigator
  • Hubs
  • Webinars
  • Store
  • Analytics
  • Insights
  • Track
  • Create
  • Newsfeed
  • Navigator
  • Hubs
  • Webinars
  • Store
  • Analytics
  • Insights
  • Track
  • Create
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Google Plus
    • Linked In
  • Follow
    Please login to follow content.
  • Like

add to folder:

  • My saved (default)
  • Read later

Register now for your free, tailored, daily legal newsfeed service.

Questions? Please contact customerservices@lexology.com

Register

European Union adopts falsified medicines directive

Sidley Austin LLP

To view this article you need a PDF viewer such as Adobe Reader. Download Adobe Acrobat Reader

European Union June 7 2011

On May 27, 2011 the Council of the European Union (Council) adopted a directive aimed at preventing falsified medicines from entering into the legal supply chain. Notably, the directive imposes obligations on all actors in the distribution chain, including importers, traders, manufacturers, distributors, and any operator who repackages a product.

Sidley Austin LLP - Maurits J.F. Lugard, Scott Bass and James C. Stansel
Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Google Plus
    • Linked In
  • Follow
    Please login to follow content.
  • Like

add to folder:

  • My saved (default)
  • Read later

Filed under

  • European Union
  • Healthcare & Life Sciences
  • Product Regulation & Liability
  • Sidley Austin LLP

Tagged with

  • Product (business)
  • Council of the European Union
  • Supply chain
  • Distributor
  • Manufacturing
  • Distribution (business)
  • Pharmaceutical drug
  • Falsifiability

Popular articles from this firm

  1. Hong Kong Issues EU Data Privacy Law Guidance on the upcoming GDPR *
  2. Financial Crimes Enforcement Network Issues New Frequently Asked Questions on Customer Due Diligence Requirement *
  3. Court of Appeals sides with industry on definition of solid waste rule *
  4. Top Ten Data Protection and Privacy Issues to Watch in 2016 *
  5. Far-Reaching EU Consumer Class Action Proposal *

If you would like to learn how Lexology can drive your content marketing strategy forward, please email enquiries@lexology.com.

Send to Create
Powered by Lexology

Related topic hubs

  1. European Union
  2. Healthcare & Life Sciences
  3. Product Regulation & Liability

Lexology Navigator Q&A

Compare jurisdictions: Life Sciences: Product Regulation and Liability

  1. European Union
  2. China
  3. Sweden
  4. More...
Chris Heaphy
General Counsel
The Taubman Company
What our clients say

"I enjoy your publication and read it religiously."

Back to Top
  • RSS feeds
  • Contact
  • Submissions
  • About
  • Terms of use
  • Cookies
  • Disclaimer
  • Privacy policy
  • Login
  • Register
  • Follow on Twitter
  • Search
Globe Business Media Group

© Copyright 2006 - 2018 Globe Business Media Group